Cargando…

Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome

This study was to compare the efficacy and safety of combined glycoprotein IIb/IIIa inhibitor (GPI) and ticagrelor versus ticagrelor in patients with acute coronary syndrome (ACS). An observational study was conducted using the Improving Care for Cardiovascular Disease in China-ACS project. Totally,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Zhi-Jiang, Xin, Shuan-Li, Chang, Chao, Zhou, Hai-Jing, Zhao, Xiu-Feng, Jiao, Feng-Hui, Chen, Chuan, Li, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853481/
https://www.ncbi.nlm.nih.gov/pubmed/33529262
http://dx.doi.org/10.1371/journal.pone.0246166
_version_ 1783645970153603072
author Xie, Zhi-Jiang
Xin, Shuan-Li
Chang, Chao
Zhou, Hai-Jing
Zhao, Xiu-Feng
Jiao, Feng-Hui
Chen, Chuan
Li, Tao
author_facet Xie, Zhi-Jiang
Xin, Shuan-Li
Chang, Chao
Zhou, Hai-Jing
Zhao, Xiu-Feng
Jiao, Feng-Hui
Chen, Chuan
Li, Tao
author_sort Xie, Zhi-Jiang
collection PubMed
description This study was to compare the efficacy and safety of combined glycoprotein IIb/IIIa inhibitor (GPI) and ticagrelor versus ticagrelor in patients with acute coronary syndrome (ACS). An observational study was conducted using the Improving Care for Cardiovascular Disease in China-ACS project. Totally, 13,264 patients with ACS and received combination therapy or ticagrelor therapy were analyzed. The primary outcome was the composite of major cardiovascular events (MACE: all-cause mortality, myocardial infarction [MI], stent thrombosis, cardiogenic shock, and ischemic stroke), and secondary outcomes included all-cause mortality, MI, stent thrombosis, cardiogenic shock, and ischemic stroke. The multivariable adjusted analysis indicated that combination therapy was associated with an increased risk of major cardiovascular events (MACE) (P = 0.001), any bleeding (P<0.001), and major bleeding (P = 0.005). Moreover, the multivariable adjusted for propensity score-matched (PSM) analysis suggested that combination therapy produced additional risk of MACE (P = 0.014), any bleeding (P<0.001), and major bleeding (P = 0.005). Moreover, PSM analysis suggested that combination therapy was associated with greater risk of stent thrombosis (P = 0.012) and intracranial bleeding (P = 0.020). Combined GPI and ticagrelor therapies did not have any beneficial effects on MACE, stent thrombosis, intracranial bleeding, any bleeding, or major bleeding.
format Online
Article
Text
id pubmed-7853481
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-78534812021-02-09 Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome Xie, Zhi-Jiang Xin, Shuan-Li Chang, Chao Zhou, Hai-Jing Zhao, Xiu-Feng Jiao, Feng-Hui Chen, Chuan Li, Tao PLoS One Research Article This study was to compare the efficacy and safety of combined glycoprotein IIb/IIIa inhibitor (GPI) and ticagrelor versus ticagrelor in patients with acute coronary syndrome (ACS). An observational study was conducted using the Improving Care for Cardiovascular Disease in China-ACS project. Totally, 13,264 patients with ACS and received combination therapy or ticagrelor therapy were analyzed. The primary outcome was the composite of major cardiovascular events (MACE: all-cause mortality, myocardial infarction [MI], stent thrombosis, cardiogenic shock, and ischemic stroke), and secondary outcomes included all-cause mortality, MI, stent thrombosis, cardiogenic shock, and ischemic stroke. The multivariable adjusted analysis indicated that combination therapy was associated with an increased risk of major cardiovascular events (MACE) (P = 0.001), any bleeding (P<0.001), and major bleeding (P = 0.005). Moreover, the multivariable adjusted for propensity score-matched (PSM) analysis suggested that combination therapy produced additional risk of MACE (P = 0.014), any bleeding (P<0.001), and major bleeding (P = 0.005). Moreover, PSM analysis suggested that combination therapy was associated with greater risk of stent thrombosis (P = 0.012) and intracranial bleeding (P = 0.020). Combined GPI and ticagrelor therapies did not have any beneficial effects on MACE, stent thrombosis, intracranial bleeding, any bleeding, or major bleeding. Public Library of Science 2021-02-02 /pmc/articles/PMC7853481/ /pubmed/33529262 http://dx.doi.org/10.1371/journal.pone.0246166 Text en © 2021 Xie et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Xie, Zhi-Jiang
Xin, Shuan-Li
Chang, Chao
Zhou, Hai-Jing
Zhao, Xiu-Feng
Jiao, Feng-Hui
Chen, Chuan
Li, Tao
Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
title Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
title_full Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
title_fullStr Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
title_full_unstemmed Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
title_short Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
title_sort combined glycoprotein iib/iiia inhibitor therapy with ticagrelor for patients with acute coronary syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853481/
https://www.ncbi.nlm.nih.gov/pubmed/33529262
http://dx.doi.org/10.1371/journal.pone.0246166
work_keys_str_mv AT xiezhijiang combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome
AT xinshuanli combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome
AT changchao combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome
AT zhouhaijing combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome
AT zhaoxiufeng combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome
AT jiaofenghui combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome
AT chenchuan combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome
AT litao combinedglycoproteiniibiiiainhibitortherapywithticagrelorforpatientswithacutecoronarysyndrome